Oak Ridge National Laboratory researchers have discovered a better way to separate actinium-227, a rare isotope essential for an FDA-approved cancer treatment.
OAK RIDGE, Tenn., Jan. 31, 2019—A new electron microscopy technique that detects the subtle changes in the weight of proteins at the nanoscale—while keeping the sample intact—could open a new pathway for deeper, more comprehensive studies of the basic building blocks of life.
Physicists turned to the “doubly magic” tin isotope Sn-132, colliding it with a target at Oak Ridge National Laboratory to assess its properties as it lost a neutron to become Sn-131.
Scientists at the Department of Energy’s Oak Ridge National Laboratory used neutrons, isotopes and simulations to “see” the atomic structure of a saturated solution and found evidence supporting one of two competing hypotheses about how ions come
A tiny vial of gray powder produced at the Department of Energy’s Oak Ridge National Laboratory is the backbone of a new experiment to study the intense magnetic fields created in nuclear collisions.
The Department of Energy’s Oak Ridge National Laboratory is now producing actinium-227 (Ac-227) to meet projected demand for a highly effective cancer drug through a 10-year contract between the U.S. DOE Isotope Program and Bayer.
“Made in the USA.” That can now be said of the radioactive isotope molybdenum-99 (Mo-99), last made in the United States in the late 1980s. Its short-lived decay product, technetium-99m (Tc-99m), is the most widely used radioisotope in medical diagnostic imaging. Tc-99m is best known ...